| Medical and Health Sciences | Lifetime | 250 | FR 3 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 197 | FR 6 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 23 | FR 3 | 99.97 |
| Gastroenterology | Lifetime | 12 | FR 1 | 99.84 |
| Oncology | Lifetime | 132 | FR 8 | 99.78 |
| Rheumatology | Lifetime | 239 | FR 11 | 99.05 |
| Pathology and Forensic Medicine | Lifetime | 340 | FR 12 | 98.70 |
| Clinical Neurology | Lifetime | 560 | FR 20 | 97.45 |
| Immunology | Lifetime | 999 | FR 37 | 96.47 |
| Cancer Research | Lifetime | 811 | FR 16 | 94.10 |
| Medical Genetics | Lifetime | 759 | FR 35 | 91.14 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 33 | FR 6 | 99.86 |
| Gastroenterology | 2021-2025 | 14 | FR 1 | 99.33 |
| Oncology | 2021-2025 | 114 | FR 11 | 99.31 |
| Rheumatology | 2021-2025 | 116 | FR 7 | 97.33 |
| Cancer Research | 2021-2025 | 175 | FR 7 | 90.55 |
| Pathology and Forensic Medicine | 2021-2025 | 342 | FR 14 | 87.83 |
| Clinical Neurology | 2021-2025 | 484 | FR 18 | 81.83 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 1 | FR 1 | 99.98 |
| Sarcoma Diagnosis and Treatment | Lifetime | 3 | FR 1 | 99.98 |
| Gastrointestinal disorders and treatments | Lifetime | 6 | FR 1 | 99.93 |
| Cardiac tumors and thrombi | Lifetime | 4 | FR 1 | 99.95 |
| Gastric Cancer Management and Outcomes | Lifetime | 12 | FR 1 | 99.93 |
| Vascular Tumors and Angiosarcomas | Lifetime | 3 | FR 1 | 99.96 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 15 | FR 1 | 99.68 |
| Soft tissue tumor case studies | Lifetime | 12 | FR 1 | 99.69 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 32 | FR 1 | 99.61 |
| Lymphoma Diagnosis and Treatment | Lifetime | 84 | FR 8 | 99.71 |
| Soft tissue tumors and treatment | Lifetime | 3 | FR 1 | 99.69 |
| Cancer Diagnosis and Treatment | Lifetime | 106 | FR 4 | 99.16 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 278 | FR 24 | 99.31 |
| Colorectal and Anal Carcinomas | Lifetime | 111 | FR 7 | 99.00 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 51 | FR 6 | 99.30 |
| CAR-T cell therapy research | Lifetime | 410 | FR 21 | 98.79 |
| Cancer Genomics and Diagnostics | Lifetime | 614 | FR 27 | 98.87 |
| Immunotherapy and Immune Responses | Lifetime | 768 | FR 29 | 98.81 |
| Tumors and Oncological Cases | Lifetime | 155 | FR 7 | 98.37 |
| Peptidase Inhibition and Analysis | Lifetime | 557 | FR 22 | 98.06 |
| Glioma Diagnosis and Treatment | Lifetime | 533 | FR 24 | 98.44 |
| Metastasis and carcinoma case studies | Lifetime | 266 | FR 3 | 97.77 |
| Lung Cancer Treatments and Mutations | Lifetime | 988 | FR 44 | 98.10 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 200 | FR 6 | 97.39 |
| Colorectal Cancer Treatments and Studies | Lifetime | 963 | FR 77 | 97.33 |
| COVID-19 and healthcare impacts | Lifetime | 812 | FR 20 | 92.68 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 840 | FR 46 | 96.57 |
| Neutropenia and Cancer Infections | Lifetime | 486 | FR 28 | 96.04 |
| Oral and Maxillofacial Pathology | Lifetime | 984 | FR 13 | 95.79 |
| Economic and Financial Impacts of Cancer | Lifetime | 710 | FR 15 | 93.38 |
| Hematological disorders and diagnostics | Lifetime | 732 | FR 32 | 91.78 |
| Beetle Biology and Toxicology Studies | Lifetime | 64 | FR 1 | 89.26 |
| Melanoma and MAPK Pathways | Lifetime | 992 | FR 34 | 91.30 |
| Chromatin Remodeling and Cancer | Lifetime | 815 | FR 53 | 84.89 |
| Tuberous Sclerosis Complex Research | Lifetime | 545 | FR 17 | 83.99 |
| Histiocytic Disorders and Treatments | Lifetime | 990 | FR 81 | 81.63 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 1 | FR 1 | 99.91 |
| Cardiac tumors and thrombi | 2021-2025 | 1 | FR 1 | 99.79 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 4 | FR 1 | 99.82 |
| Gastrointestinal disorders and treatments | 2021-2025 | 4 | FR 1 | 99.53 |
| Bone Tumor Diagnosis and Treatments | 2021-2025 | 4 | FR 1 | 99.25 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 2 | FR 1 | 99.61 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 5 | FR 1 | 99.06 |
| Cancer Diagnosis and Treatment | 2021-2025 | 15 | FR 3 | 97.20 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 120 | FR 5 | 98.70 |
| Cancer Genomics and Diagnostics | 2021-2025 | 230 | FR 10 | 98.25 |
| CAR-T cell therapy research | 2021-2025 | 438 | FR 23 | 97.26 |
| COVID-19 and healthcare impacts | 2021-2025 | 403 | FR 9 | 93.74 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 299 | FR 22 | 97.15 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 32 | FR 1 | 94.51 |
| Soft tissue tumors and treatment | 2021-2025 | 6 | FR 1 | 93.44 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 218 | FR 7 | 93.49 |
| Colorectal and Anal Carcinomas | 2021-2025 | 377 | FR 28 | 91.05 |
| Soft tissue tumor case studies | 2021-2025 | 86 | FR 9 | 87.44 |
| Tumors and Oncological Cases | 2021-2025 | 175 | FR 17 | 84.60 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 522 | FR 28 | 75.88 |
| Histiocytic Disorders and Treatments | 2021-2025 | 219 | FR 28 | 68.35 |
| Melanoma and MAPK Pathways | 2021-2025 | 935 | FR 40 | 67.74 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 843 | FR 30 | 29.05 |
